Prevalence of aminoglycoside therapy and other determinant factors that induce hearing loss in neonates

Nassor R. Hamad; Retnosari Andrajati; Rina Mutiara; Risma Kerina Kaban; Rajesh Kumar Das

doi:10.18203/issn.2454-5929.ijohns20203190

Authors

Nassor R. Hamad Faculty of Pharmacy, University of Indonesia, Indonesia
Retnosari Andrajati Department of Pharmacy, University of Indonesia, Indonesia
Rina Mutiara Department of Pharmacy, University of Indonesia, Indonesia
Risma Kerina Kaban Department of Medicine, University of Indonesia, Indonesia
Rajesh Kumar Das Department of Epidemiology, University of Indonesia, Indonesia

DOI:

https://doi.org/10.18203/issn.2454-5929.ijohns20203190

Keywords:

Aminoglycoside therapy, Hearing loss, Neonates

Abstract

Background: Hearing loss is the most common disorder in neonates; it can be best managed if it is diagnosed at early stage of life. The global prevalence of permanent neonatal hearing loss mainly occurs in developing countries, which accounts 0.5 to 5.0 per 1000 live births. The objective of this study was to determine the prevalence of aminoglycoside therapy and other risk factors that induce hearing loss in neonates admitted at NICU at Cipto-Mangunkusumo General Hospital (CMGH).

Methods: This was a case-control study conducted among 112 neonates at Cipto-Mangunkusumo General Hospital (CMGH). Data from neonatal hearing screening were retrospectively collected from hospital electronic medical records and medical files. Only patients treated at neonatal unit from November 2018 to October 2019 were recruited.

Results: Out of 112 neonates studied, the gestational age at birth (GA) and craniofacial anomalies were considered risk factors for hearing loss since they were statistically significant (p<0.05). The study showed no statistical significant association in gender, birth weight, mechanical ventilation, NICU stay period (>5 days), hyperbilirubinemia (>20 mg/dl), asphyxia, and aminoglycoside therapy (p>0.05).

Conclusions: The prevalence of hearing loss in neonates with lower gestational age less than 37 weeks and craniofacial anomalies are significant higher compare to neonates born full term. They are more associated with 3 and 6 times increased risk of hearing loss in neonates.

Metrics

Metrics Loading ...

Author Biography

Nassor R. Hamad, Faculty of Pharmacy, University of Indonesia, Indonesia

Department of pharmaceutical science

References

Yoshikawa S, Ikeda K, Kudo T, Kobayashi T. The effects of hypoxia, premature birth, infection, ototoxic drugs, circulatory system and congenital disease on neonatal hearing loss. Auris Nasus Larynx. 2004;31(4):361-8.

Maharani NL, Haksari EL, Artana IW. Risk factors for hearing loss in neonates. Paediatrica Indonesiana. 2015;55(6):328-32.

Neumann K, Chadha S, Tavartkiladze G, Bu X, White KR. Newborn and infant hearing screening facing globally growing numbers of people suffering from disabling hearing loss. Int J Neonat Screening. 2019;5(1):7.

Kountakis SE, Skoulas I, Phillips D, Chang CJ. Risk factors for hearing loss in neonates: a prospective study. Am J Otolaryngol. 2002;23(3):133-7.

Miguel J, Canet S, Miguel C, Romero A, Miguel J, Sabater S, et al. Otoacoustic emissions in children treated with gentamicin in a secondary hospital. Acta Otorrinolaringol 2018;69(5):291-6.

Karaca ÇT, Oysu Ç, Toros SZ, Naiboǧlu B, Verim A. Is hearing loss in infants associated with risk factors? Evaluation of the frequency of risk factors. Clin Exp Otorhinolaryngol. 2014;7(4):260-3.

Puia-dumitrescu M, Bretzius OM, Brown N, Fitz-henley JA, Ssengonzi R, Wechsler CS, et al. Evaluation of gentamicin exposure in the neonatal intensive care unit. J Pediatr. 2014;203:131-6.

Lachowska M, Surowiec P, Morawski K, Pierchała K. Advances in medical sciences second stage of universal neonatal hearing screening- a way for diagnosis and beginning of proper treatment for infants with hearing loss. Adv Med Sci. 2014;59(1):90-4.

van Dommelen P, Verkerk PH, van Straaten HL, Baerts W, Von Weissenbruch M, Duijsters C, van Kaam A, Steiner K, de Vries LS, Swarte R, Sprij AJ. Hearing loss by week of gestation and birth weight in very preterm neonates. J Pediatr. 2015;166(4):840-3.

Bielecki I, Horbulewicz A, Wolan T. Risk factors associated with hearing loss in infants : An analysis of 5282 referred neonates. Int J Pediatr Otorhinolaryngol. 2011;75(7):925-30.

Wroblewska-seniuk K, Dabrowski P, Greczka G, Szabatowska K, Glowacka A, Szyfter W, et al. Sensorineural and conductive hearing loss in infants diagnosed in the program of universal newborn hearing screening. Int J Pediatr Otorhinolaryngol. 2018;105:181-6.

Boskabadi H, Zakerihamidi M, Moradi A, Bakhshaee M. Risk factors for sensorineural hearing loss in neonatal hyperbilirubinemia. Iranian J Otorhinolaryngol. 2018;30(99):195.

Petersen L, Rogers C. Aminoglycoside-induced hearing deficits- a review of cochlear ototoxicity. South African Fam Pract. 2015;57(2):1-6.

O’Sullivan ME, Perez A, Lin R, Sajjadi A, Ricci AJ, Cheng AG. Towards the prevention of aminoglycoside-related hearing loss. Front Cell Neurosci. 2017;11:1-14.

Selimoglu E. Aminoglycoside-induced ototoxicity. Current Pharm Des. 2007;13(1):119-26.

Setiabudy R, Suwento R, Rundjan L, Yasin FH, Louisa M, Dwijayanti A, et al. The lack of relationship between serum concentration of aminoglycosides and its ototoxicity in neonates. Int J Clin Pharm Therap. 2013;2013:1-6.

Holster IL, Hoeve LJ, Wieringa MH, Willis-lorrier RMS, Gier HHW De. Evaluation of hearing loss after failed neonatal hearing screening. J Pediatr. 2009;155(5):646-50.

Cristobal R, Oghalai JS. Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology. Arch Dis Child Fetal Neonatal Ed. 2008;93(6):462-8.